BRAF and neoplasm: For example, targeting mitogen-activated protein kinase (MAPK) pathway utilizing EGFR/MEK/BRAF inhibitors was shown to induce the expression of tumor neoantigens, promote the infiltration of CD8+ T cells to the tumor site and block the canonical oncologic signaling pathways (16).